Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Cash & Equivalents

Cash on hand and highly liquid investments that can be converted to cash almost immediately.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Cash & Equivalents · Q1 FY2026 · quarter ended Mar 2026

Cash & equivalents falls 26.0% from a year ago

Cash & equivalents stood at $3.08M at the end of Q1 FY2026, down 26.0% from a year earlier and down 40.1% from the prior quarter.

Context

  • Cash & equivalents amounted to 87.9% of total assets at the end of Q1 FY2026, down 5.8 pp from a year earlier.
  • Cash & equivalents increased in 2 of the last 2 fiscal years.
  • FY2025 was the highest annual figure in the 3 fiscal years shown.

What to watch

Whether cash & equivalents keeps falling in the next quarterly balance sheet after a -26.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$3.08M-40.1% QoQ
Last fiscal yearDec 2025
$5.14M+11.3% YoY
Year agoMar 2025
$4.16M-26.0% since
Cash & Equivalents past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-26.0%——
1 year+11.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Cash & Equivalents history

USD · from the balance sheet

Latest · FY2025
5.14M USD
Year-over-year change
+11.3%
2-year CAGR
+4971.0%

Cash & Equivalents vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's Mar 2026 cash & equivalents of $3.08M is the lowest of the 8 companies compared; the peer median is $55.09M.
  • Its year-over-year change of -26.0% is the 7th highest of 8, against a peer median of +45.7%.
  • Cash & equivalents amounts to 87.9% of total assets for PLYX, versus a peer median of 31.4%.
PLYX Competitors Peer median
Cash & Equivalents for PLYX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
CBIOCrescent Biopharma, Inc.Mar 2026$189.16M +3269.4%+64.5%95.0%
LYELLyell Immunopharma, Inc.Mar 2026$90.77M -24.6%-21.3%25.9%
FHTXFoghorn Therapeutics Inc.Mar 2026$88.91M +45.7%+15.7%40.0%
JBIOJade Biosciences, Inc.Mar 2026$55.09M +24.6%+58.1%17.2%
ANTXAN2 Therapeutics, Inc.Mar 2026$53.49M +167.6%-9.9%61.1%
KLRSKalaris Therapeutics IncMar 2026$34.43M -65.9%+217.7%31.4%
PTHSPelthos Therapeutics Inc.Mar 2026$32.23M +24440.6%+589.1%22.2%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$3.08M -26.0%—87.9%
Peer median (excluding PLYX) $55.09M+45.7%+58.1%31.4%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.